glow: assessing ibrutinib plus venetoclax in cll
Published 2 years ago • 358 plays • Length 1:54Download video MP4
Download video MP3
Similar videos
-
3:34
glow: primary analysis of ibrutinib plus venetoclax versus obinutuzumab plus chlorambucil in cll
-
3:09
mrd outcomes from glow: venetoclax and ibrutinib in cll
-
2:45
optimizing the combination of ibrutinib plus venetoclax in cll
-
2:18
first-line ibrutinib and venetoclax in cll
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
5:29
long term follow-up with ibrutinib venetoclax to treat chronic lymphocytic leukemia
-
3:53
flash and glow luminescence - science tutor #1
-
7:28
watsons glow tv ep44 | jelisa & vistoria share products you need for this valentine's day!
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
1:56
emerging ibrutinib-based combinations in cll
-
2:37
next steps for genetic testing in cll
-
1:14
novel inducers of apoptosis in double-refractory cll cells
-
2:06
effects of dose adjustment of first-line ibrutinib on real-world dosing patterns and outcomes in cll
-
1:47
ash cll highlights: ibrutinib-venetoclax combination & undetectable mrd in ighv-mutated patients
-
2:51
genetic markers in patients with early-stage cll treated with ibrutinib: findings from cll12
-
2:00
ibrutinib: use in small cll subgroups only?
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
1:01
selinexor for cll - mechanism of action and combination with ibrutinib
-
0:53
all-cll: an ngs panel for molecular characterization of cll
-
4:05
bcl2 and btk dual-inhibition with sonrotoclax zanubrutinib in previously untreated cll and sll